Form 4: CalciMedica CSO Reports Insider Transactions and Short-Swing Profit Repayment

CalciMedica's Chief Scientific Officer, Kenneth A. Stauderman, reported recent stock transactions, including a sale by his spouse that resulted in a short-swing profit violation requiring repayment to the company.

Summary

• Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., filed a Form 4 detailing recent stock transactions.
• On July 25, 2025, his spouse sold 1,000 shares of CalciMedica common stock at $3.65 per share.
• On July 28, 2025, Mr. Stauderman purchased 1,000 shares of CalciMedica common stock at $3.96 per share, increasing his direct beneficial ownership to 12,944 shares.
• The spouse's sale on July 25, 2025, was matchable under Section 16(b) of the Securities Exchange Act of 1934 with a prior purchase of 1,000 shares by the spouse on July 1, 2025, at $1.85 per share.
• This resulted in a short-swing profit of $1,799.83, which Mr. Stauderman has agreed to pay to CalciMedica, Inc.

Sentiment

Score: 4

Explanation: The insider purchase is a positive signal, but the short-swing profit violation and required repayment introduce a negative element related to compliance and oversight, slightly dampening overall sentiment.

Positives

• The Chief Scientific Officer purchased 1,000 shares of common stock, potentially signaling confidence in the company's future.

Negatives

• A short-swing profit violation occurred, requiring the Chief Scientific Officer to repay $1,799.83 to the company.
• The spouse's sale of 1,000 shares occurred at a lower price ($3.65) than the subsequent purchase by the reporting person ($3.96).

Risks

• Compliance risk due to the Section 16(b) short-swing profit violation, which requires repayment of realized gains.
• Reputational risk for the executive and the company due to the compliance oversight.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report (Form 4) and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector. Its primary focus is on individual executive stock ownership and compliance.

Corporate Governance

Legal Proceedings

• The filing details a Section 16(b) short-swing profit violation, which is a regulatory matter requiring the disgorgement of profits to the company.

Related Party Transactions

• The sale of common stock by the reporting person's spouse is considered a related party transaction, which led to the short-swing profit violation.

Stakeholder Impact

• Shareholders: The company will receive $1,799.83 from the executive due to the short-swing profit violation. The executive's purchase of shares could be seen as a positive signal of confidence.
• Management: The Chief Scientific Officer is directly impacted by the requirement to repay the short-swing profit.

Next Steps

• The reporting person is expected to pay $1,799.83 to CalciMedica, Inc. upon settlement of the sale to resolve the short-swing profit violation.

Key Dates

Recommendation

The filing primarily details routine insider stock transactions and a minor compliance issue related to a short-swing profit. While the Chief Scientific Officer's purchase of shares could be interpreted as a positive signal of confidence, the required repayment for a Section 16(b) violation introduces a slight negative. Neither event is significant enough to warrant a strong buy or sell recommendation, suggesting a 'hold' position as the core business operations and financial performance remain the primary drivers for investment decisions.

Keywords

CalciMedica, CALC, Form 4, Insider Trading, Section 16(b), Short-Swing Profit, Kenneth A. Stauderman, Chief Scientific Officer, Stock Transactions, Compliance, Biotechnology, Pharmaceuticals